Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.

Finasteride and dutasteride are the most evidence-supported pharmacological treatments for androgenetic alopecia (AGA) in both men and women. Finasteride 1 mg/day reduces serum DHT by about 70%, while dutasteride 0.5 mg/day achieves approximately 90% suppression, with dutasteride showing slightly greater hair count gains. A pivotal trial found dutasteride 2.5 mg superior to finasteride 5 mg/day, but the 0.5 mg dose is standard due to its efficacy and lower systemic exposure. Genetic factors, particularly androgen receptor variations, significantly influence treatment response. In women, higher doses of finasteride and variable doses of dutasteride are effective, especially in postmenopausal and some premenopausal groups. The choice between these drugs involves balancing DHT suppression, drug half-life, and tolerability, with genetic modifiers being an important area for future research.

This study investigates the degradation profile of finasteride, a drug used for benign prostatic hyperplasia and androgenetic alopecia, under stress conditions. Using LC–MS, three degradation products were identified under acidic conditions, with minimal degradation in alkaline and oxidative environments. The degradation products were isolated and analyzed using preparative HPLC, HRMS, and NMR spectroscopy. The study revealed that the degradation process of DP-1 involved cleavage of the tert-butyl amide and addition of water across the alkene moiety. The structure of DP-1 was established through various spectroscopic techniques, and it, along with other degradation products, was found to be previously undescribed. These findings enhance the understanding of finasteride's degradation chemistry, aiding impurity profiling, stability studies, and quality control of its formulations.